Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Smarter Blood Tests Deliver Faster Diagnoses and Improved Outcomes

By LabMedica International staff writers
Posted on 19 Nov 2024

It has long been established that the earlier a disease is detected, the better the chances for a positive patient outcome. More...

A novel method now offers an in-depth analysis of proteins in plasma, uncovering biomarkers that can help researchers and eventually clinicians identify diseases at an earlier stage.

This pioneering methodology for deep analysis of proteins in plasma was developed by a multidisciplinary team of researchers from Michigan State University (East Lansing, MI, USA), in collaboration with other experts. The new approach minimizes the interference from common blood proteins, making it possible to detect lesser-known, low-abundance proteins that are often key in diagnosing diseases. By introducing small molecules into the blood sample, these important proteins are exposed on the surface of nanoparticles, enhancing their visibility for analysis through mass spectrometry—a technique that separates and examines ionized particles using electric and magnetic fields.

This breakthrough testing method, published in Nature Communications, contributes to the advancement of precision medicine. Unlike the traditional "one-size-fits-all" treatment approach, precision medicine customizes healthcare for an individual's genetics, environment, and lifestyle, offering more targeted and effective solutions. This approach has shown particular promise in fields like cancer research, where tumor genetic profiling can result in improved outcomes and reduced side effects.

“Our innovative approach significantly reduces the masking effects of highly abundant plasma proteins, which often hinder the detection of critical biomarkers in human plasma,” said Morteza Mahmoudi, associate professor in the Department of Radiology and Precision Health Program in the MSU College of Human Medicine. “By minimizing these interactions, we can increase the visibility and identification of low-abundance proteins, making it easier to detect important biomarkers that would otherwise remain hidden. This enhancement leads to improved diagnostic capabilities, allowing for more precise and earlier detection of diseases.”


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Portable Electronic Pipette
Mini 96
Alcohol Testing Device
Dräger Alcotest 7000
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.